Novel platform uses DNA-loaded polymeric nanoparticles to precisely reprogram cells in patients, offering potential to reset the immune system and transform treatment for life-threatening autoimmune diseases 

ImmunoVec will conduct the multi-year award in collaboration with world-renowned researchers at Johns Hopkins University, MD Anderson and other U.S. institutions

LOS ANGELES, Oct. 8, 2025 — ImmunoVec, a biotechnology company pioneering a novel approach to in vivo cell engineering, today announced its launch from stealth with an up to $40.7 million award from the Advanced Research Projects Agency for Health (ARPA-H) Engineering of Immune Cells Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The funding will accelerate development of ImmunoVec’s first-in-class in vivo cell therapy for autoimmune diseases, from pre-clinical studies through a first-in-human clinical trial.

ImmunoVec will conduct the project in collaboration with world-renowned researchers at Johns Hopkins University, The University of Texas MD Anderson Cancer Center, and other U.S. institutions. Together, the team will evaluate the ability of ImmunoVec’s DNA-loaded polymeric nanoparticle platform to precisely reprogram immune cells in patients, reset the immune system and transform treatment of multiple, serious autoimmune diseases.

“We are very grateful to ARPA-H for this award, which provides incredible validation for ImmunoVec’s differentiated approach to in vivo cell engineering,” said Ryan Wong, Ph.D., ImmunoVec CEO and co-founder. “By precisely reprogramming immune cells directly within the body, we aim to overcome the fundamental limitations of current cell therapies, and deliver safer, more potent, and far more accessible treatments at an unprecedented scale, speed, and cost.”

Most emerging viral and non-viral in vivo cell engineering approaches are expensive to manufacture and lack cell-type specificity, limiting their scalability and creating safety concerns due to off-target effects. The ImmunoVec platform circumvents these challenges through a dual-precision design that pairs targeted polymer-based DNA delivery vehicles with proprietary, cell type-specific promoters that exclusively deliver the therapeutic payload within the intended cell population.

Unlike viral vectors and lipid nanoparticles, ImmunoVec’s biodegradable polymers are low-cost, scalable, and non-immunogenic, offering the potential for a safer and more flexible manufacturing process. In parallel, its DNA-based payload enables durable, long-term expression, a key advantage over transient mRNA systems. This dual-regulation strategy has the potential to provide unprecedented control, therapeutic efficacy, and safety by ensuring genetic therapies are delivered and expressed only by the desired cell types.

ImmunoVec’s ARPA-H-funded project will apply the company’s platform to develop a novel polymeric nanoparticle capable of engineering natural killer (NK) cells in vivo with a CD19-targeted chimeric antigen receptor (CAR) construct. This approach aims to deplete B cells that cause autoimmune disease (autoreactive cells), and offers significant advantages over traditional ex vivo CAR therapies.

“We founded ImmunoVec to translate this promising, next-generation, cell type-specific platform into the clinic, led by a team with a rare blend of scientific innovation and operational excellence,” said William Woodward, ImmunoVec chairman, co-founder, and managing general partner at Anthem Venture Partners.

ImmunoVec’s platform is de-risked and validated, and the team has a track record of advancing potentially curative therapies toward the clinic. The company has developed a pipeline of cell type-specific gene therapies for multiple, potentially fatal pediatric immune diseases, such as X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome and IPEX syndrome. Pre-clinical data demonstrate that these therapies restore normal gene expression and have the potential to safely and effectively reduce or eliminate symptoms of these serious illnesses.

“We created ImmunoVec to fundamentally change how gene and cell therapies are delivered,” said Luke Riggan, Ph.D., director of Cell Therapy at ImmunoVec. “Compared to ex vivo CAR-T therapies, which can be slow and prohibitively expensive, our in vivo approach can be delivered in days, at a fraction of the cost, and potentially reach far more patients.”

In addition to the ARPA-H-funded project, ImmunoVec is advancing a series of preclinical programs utilizing its platform to create next-generation cell therapies for autoimmune diseases, solid tumors, and genetic disorders. The company is also securing funding as part of a Series A financing to accelerate its development pipeline.

About ImmunoVec
ImmunoVec is pioneering the next generation of in vivo cell engineering, developing therapies for autoimmune diseases, solid tumors, and genetic disorders. The company’s proprietary platform combines synthetic, cell type-specific promoters across multiple delivery vehicles to enable precise and durable expression of therapeutic payloads within targeted cells. ImmunoVec is led by scientific Co-Founders Ryan Wong, Ph.D., and Luke Riggan, Ph.D., along with Chairman William Woodward, a renowned venture capitalist and serial entrepreneur, and Doug Sills of Anthem Venture Partners. The company operates out of the California NanoSystems Institute (CNSI) in Los Angeles, providing access to world-class facilities and collaborations with leading scientists. For more information, visit https://immunovec.com/

This research was funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. Government.

SOURCE ImmunoVec

BERMUDA and HONG KONG, Oct. 8, 2025 — Anthea Holding Limited, the global cryptofintech group offering life insurance products denominated in cryptocurrencies through its wholly-owned subsidiary Anthea Insurance Limited (collectively, “Anthea”), today announced it has secured US$22 million in Series A financing. The innovator, whose vision is to combine life insurance with digital assets, has attracted meaningful interest from global investors. The funding round was led by Yunfeng Financial Group Limited (stock code: 00376.HK), alongside a diverse group of strategic and financial investors with expertise spanning insurance, asset management, and fintech innovation.

The capital raise marks a new chapter in Anthea’s mission to redefine life insurance for the digital age. The capital infusion will enable the launch of Anthea’s firstlife insurance product denominated in ETH(Ethereum) — also the world’s first Ethereum life insurance product ever. In addition, it will support Anthea’s ongoing business operations, accelerate product development and innovation, and expand distribution networks and market presence across Asia.

“This funding round is more than capital — it is a strategic alignment with partners who share our vision for the future of insurance,” said Alex Pei, CEO of Anthea. “The past few years have seen the rise of regulated and consumer-centric products and institutions in the digital asset space; it is now time to bring the right combinationof innovation and protection to the market. We are delighted to welcome investors with decades of experience in traditional finance and a shared appetite for innovation. Together, we are building a global platform where digital assets and life insurance converge.”

Anthea’s Series A funding round follows Anthea Insurance Limited’s recent in-principle approval from the Bermuda Monetary Authority (BMA) to register as an Innovative Insurer. Capital support from this funding round will further strengthen Anthea’s commitment to organically embedding global best practice life insurance into the digital asset ecosystem — supporting integration with blockchain-based payment infrastructure, enabling yield generation, and pursuing strategic innovations. Anthea aims to create a seamless insurance experience tailored for both digital asset holders and traditional investors seeking regulated exposure to the digital asset space.

About Anthea

Anthea is a Bermuda-based crypto life insurance company offering digital currency-denominated insurance products under the BMA’s Innovative Insurer regime. With a focus on regulatory compliance, customer-centricity, and strategic partnerships, Anthea is building the future of life insurance in the digital asset ecosystem.

About Yunfeng Financial Group

Yunfeng Financial Group Limited (Stock Code: 00376.HK) is an innovative fintech company whose major shareholders include Yunfeng Financial Holdings Limited and MassMutual. Its business spans insurance, securities brokerage, asset management, and fintech. The Group holds Type 1, 4, and 9 licenses from the Hong Kong Securities and Futures Commission through its subsidiaries, and with its controlling stake in MassMutual Insurance, the Group also holds a long-term insurance license and MPF trustee qualification from the Hong Kong Insurance Authority.

For more information on Anthea and the capital raise, contact [email protected].

SOURCE Anthea

• Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026

SAN DIEGO, Oct. 8, 2025 — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced the closing of its $153 million Series E financing led by Prime Eight Capital Limited and with participation from CR Biotech,HighLight Capital, HM Venture Partners, , ReliantTech Limited and existing shareholders.

Arthrosi plans to use the proceeds from this financing to complete the clinical development of its lead program, pozdeutinurad (AR882), through its replicate Phase 3 REDUCE 1 and REDUCE 2 studies evaluating pozdeutinurad for the treatment of gout and tophaceous gout. These twelve-month, randomized, double-blind, placebo-controlled studies are designed to assess pozdeutinurad’s ability to reduce sUA in patients with gout and tophaceous gout. Secondary endpoints include reduction in flares and tophi over time. Both Phase 3 trials are now fully enrolled, and the Company expects to report pivotal data in Q2 2026.

“We are delighted to have the continued support of an experienced and deeply committed group of investors,” said Litain Yeh, Ph.D., Founder and CEO of Arthrosi Therapeutics. “Arthrosi continues to make rapid progress on our mission to transform the treatment landscape for gout and tophaceous gout, an area with pressing unmet need. The commitment from both new and existing investors provides further validation for pozdeutinurad and the robust clinical data package we have generated to date. With their support, we look forward to advancing our pivotal Phase 3 program as we work to deliver pozdeutinurad’s potentially transformative benefits to patients as soon as possible.”

“We’re excited to partner with Arthrosi as they advance pozdeutinurad through late-stage development,” said Prime Eight Capital. “The company’s strong management team with a focus on execution gives us confidence in Arthrosi’s ability to deliver a potentially best-in-class treatment for gout. We share their vision to make pozdeutinurad accessible to patients globally and are proud to support a team with the expertise, discipline, and urgency to make that vision a reality.”

About Arthrosi:
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad (AR882), a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout. Pozdeutinurad has demonstrated encouraging efficacy and safety compared to SOC in Phase 2 studies as well as impressive results in achieving complete resolution of tophi in a Phase 2b study. Arthrosi is currently advancing pozdeutinurad in a pivotal Phase 3 program.

About Gout:
In the U.S., an estimated 13 million individuals are diagnosed with gout, ~2 million of which have tophaceous gout. Gout is a form of inflammatory arthritis that can significantly diminish mobility, functionality, and overall quality of life. Gout emerges from the crystallization of uric acid within the joints and soft tissue, instigating painful flare-ups and chronic symptoms. The kidneys play a pivotal role in the process, as they are responsible for filtering out and excreting uric acid from the body. In over 90% of gout patients, underexcretion of uric acid results in the imbalanced and elevated sUA levels that can lead to the deposition of uric acid crystals. It’s essential to monitor and manage sUA levels as part of comprehensive gout treatment and prevention strategies.

Arthrosi Contact:
Shunqi Yan, PhD
Founder & Chief Operating Officer
[email protected]

Precision AQ Contact:
Alex Lobo
212-698-8802
[email protected]

SOURCE Arthrosi Therapeutics

Wesley Bryan named President of BPaaS Services.

ORLANDO, Fla., Oct. 8, 2025 — Veritas Prime, a leading provider of SAP Technology Solutions & Services, announced today that it has finalized a $31.5 million strategic investment to accelerate the expansion of its Business Process as a Service (BPaaS) offerings and strengthen its SAP S/4 Finance practice.

The investment comes from a leading private equity firm with deep expertise in the BPaaS sector, underscoring Veritas Prime’s growing position as a trusted partner for enterprises modernizing their HR and finance operations. The identity of the firm will be announced at a later date.

“This investment marks a pivotal milestone for our company,” said Mike Pappis, CEO of Veritas Prime. “As organizations increasingly look to optimize business outcomes through scalable, cloud-based services, Veritas Prime is uniquely positioned to deliver integrated SAP solutions that bridge technology, process, and people. The backing of a strategic investor further validates our vision and momentum in the BPaaS space.”

As part of this growth strategy, Veritas Prime also announced the appointment of Wesley Bryan as President of BPaaS Services. Wes brings a wealth of experience and a proven track record in building and scaling BPaaS delivery models within enterprise ecosystems.

“Wesley is an exceptional leader who understands both the operational and strategic dimensions of BPaaS,” said Pappis. “His experience driving large-scale transformation initiatives will be instrumental as we continue to expand and refine our service offerings.”

“I’m thrilled to join at such an exciting time,” said Bryan. “The combination of Veritas Prime’s SAP Payroll expertise, client-first culture, and innovation mindset positions the company for significant growth. I look forward to leading our BPaaS initiatives and helping clients achieve even greater agility and value.”

With this infusion of capital and leadership expansion, Veritas Prime is poised to further invest in technology, talent, and partnerships that enhance its ability to deliver end-to-end SAP solutions globally.

About Veritas Prime
Veritas Prime is a global SAP consulting and technology services firm specializing in SAP SuccessFactors, SAP Payroll, and SAP S/4HANA solutions. With a commitment to innovation, quality, and client success, Veritas Prime helps organizations transform HR and finance operations through integrated technology and managed services.

SOURCE Veritas Prime

SAN FRANCISCO, Oct. 8, 2025 — AiPrise, the company building the operating system for global compliance, today announced it has raised $12.5 million in Series A funding to accelerate its mission of helping businesses streamline KYC and KYB processes, reducing onboarding from weeks to minutes across 150+ countries.

The round was led by Headline, with participation from Y Combinator, SixThirty Ventures, Correlation Ventures, and a select group of strategic angels. Since graduating from Y Combinator’s Summer 2022 batch, AiPrise has grown to 150+ global customers and a 40-person team, powering onboarding for leading enterprises, including Bridge (a Stripe Company) and D.Local.

Onboarding across borders is harder than ever. Regulations vary by country, systems don’t connect, and fraud tactics from deepfakes to synthetic identities are moving faster than most companies can keep up. Traditionally, companies stitch together multiple point solutions to manage compliance, juggling vendors and integrations across regions. This approach is slow, expensive, and brittle. AiPrise solves this with orchestration.

AiPrise takes a full-stack approach to compliance, uniting three powerful layers into one seamless solution: data from 80+ local registries worldwide, a platform with advanced decisioning and case management tools, and AI agents that automate reviews and speed resolution. By bringing these elements together, AiPrise enables global businesses to onboard customers faster, reduce risk, and scale with confidence.

“Global companies shouldn’t have to rebuild compliance infrastructure every time they expand into a new country,” said Chaitanya Sarda, Co-founder and CEO of AiPrise. “We’re thrilled to have the support from Headline, who made a dozen introductions to companies in their network. With this Series A funding, we’re expanding our product and team to meet growing demand. Our goal is to give companies a single, intelligent layer for onboarding and compliance so they can focus on growth while we handle the complexity behind the scenes.”

While most compliance tools solve for a single piece of the puzzle, such as document scanning or registry access, AiPrise addresses the entire compliance journey. By owning the orchestration logic, AiPrise provides a modular, composable platform that adapts to customers’ systems rather than forcing them to adopt a new stack. Enterprises can integrate AiPrise once and then launch into new markets instantly, with consistent verification and fraud controls across geographies.

“When we first met AiPrise, it was clear they weren’t just building another KYC tool,” said Thomas Gieselmann, Founding Partner at Headline. “They’re building the orchestration layer global companies need to operate confidently. By converting several prospective customers, we connected them with paying customers. AiPrise has shown both strong product-market fit and the urgency of the problem they’re solving.”

This growth reflects a broader market shift as companies increasingly default to global expansion from day one, requiring a compliance partner that can keep pace with evolving regulations and fraud risks.

“Compliance should empower growth, not hold it back. With this funding, we’re building a smarter, unified platform that transforms fragmented, manual processes into secure, scalable solutions. Our mission is to enable global businesses to fight fraud, scale with confidence, and focus on what matters most: their customers,” said Rushabh Shah, Co-founder and Co-CEO of AiPrise.

About AiPrise

AiPrise is a compliance technology company building the first global orchestration layer for risk, compliance, and fraud detection. By unifying 80+ local and international vendors into one adaptive platform, AiPrise enables companies to verify and onboard customers, vendors, and partners anywhere in the world in minutes, not weeks. With more than 150 customers globally and backing from top investors, including Headline, Y Combinator, SixThirty, and Correlation Ventures, AiPrise is redefining compliance for the borderless economy. Learn more at www.aiprise.com.

SOURCE AiPrise

HANGZHOU, China, Oct. 8, 2025 — Jiuzi Holdings, Inc. (NASDAQ: JZXN; the “Company”) today announced the implementation details of its previously disclosed US$1 billion capital plan. The Company intends to raise funds through market investors and execute the plan via an ongoing purchase program, capped at US$1 billion.

Following the initial announcement, the Company further clarified that the capital structure will take a diversified form. Jiuzi has held extensive discussions with institutional investors, long-term value investors, and strategic partners, and has received positive investment intentions. The funding sources are expected to include market financing, additional commitments from existing shareholders, revenue generated from operations, and participation from institutional investors. This diversified mix not only reflects the capital market’s strong recognition of the Company’s fundamentals and strategy but also provides solid assurance for the smooth execution of the plan.

Tao Li, CEO of Jiuzi Holdings, commented: “We are encouraged by the strong support this plan has received from investors with diverse backgrounds. It represents not only recognition of our achievements but also confidence in our ability to deliver future value. A solid foundation of long-term, strategic capital will empower us to pursue our goals with greater confidence.”

The capital plan is designed to expand global market share, optimize the capital structure, and enhance long-term shareholder value. By introducing diversified capital and following a disciplined execution process, JZXN aims to consolidate its leadership position and capture new growth opportunities. Initial purchases under the plan are expected to begin within two weeks.

The Company reaffirmed that all transactions will be conducted transparently and in full compliance with applicable laws, regulations, and market rules. Updates will be disclosed in a timely manner to ensure all investors have equal access to information.

This announcement marks a significant milestone for JZXN as it embarks on the next phase of growth and positions itself for long-term success.

About Jiuzi Holdings, Inc.

Jiuzi Holdings, Inc. is a leading provider of new energy vehicle (NEV) intelligent charging infrastructure in China’s lower-tier cities. The Company specializes in high-power DC fast charging stations integrated with energy storage systems and plans continued expansion through 2026 to support China’s carbon neutrality goals and sustainable transportation. For more information, visit jzxn.com.

SOURCE Jiuzi Holdings, Inc

WASHINGTON, Oct. 7, 2025 — Increase Alpha, LLC, a fintech startup founded by former U.S. government AI policy advisor Sid Ghatak, today announced it has raised US$3.5 million in seed funding to launch its equity predictive signal engine for hedge funds and institutional investors. The round was led by Bartt Kellermann, CEO of Battle of the Quants.

Powered by its proprietary Predictive Artificial Intelligence (PAI), Increase Alpha’s predictive engine has generated 90% cumulative excess returns (“alpha”) over the past three years. While most hedge funds aspire for 52-55% accuracy—Increase Alpha exploits an information gap to identify a tradable set of hundreds of equities with an average accuracy of 70%. Designed for seamless integration into existing investment strategies, the engine offers ready-to-use signals for hedge funds without requiring internal data cleansing or signal processing as is typically the case with other alternative data providers.

“In an industry where unique, uncorrelated, and consistent alpha has become increasingly rare, we’ve demonstrated that it’s not only possible, but scalable,” said Sid Ghatak, Founder and CEO of Increase Alpha.

The announcement comes with the tailwind of an especially auspicious month—Zanista, an AI-powered financial analytics firm, has published a research paper on Increase Alpha, entitled “Increase Alpha: Performance and Risk of an AI-Driven Trading Framework,” Increase Alpha sponsored the Eagle Alpha conference where it formally introduced its product to the hedge fund industry, and Sid testified before Congress on how to develop AI solutions to improve care for the nation’s veterans.

The launch comes at a time when financial institutions are exploring the use of Generative AI to inform and identify trading strategies in the hopes of uncovering alpha. Yet, many existing LLMs solutions remain experimental as they often struggle to handle the complexities of the capital markets, they lack the transparency required for the financial industry, and their ongoing issues with hallucinations. According to a recent well publicized MIT Study regarding the failure of Generative AI projects, the financial services industry showed “little to no structural change” as a result of Generative AI.

Increase Alpha closes this gap through its Predictive AI platform that does not use any LLM technologies and was purpose-built for financial markets. Unlike traditional models, its engine is built and tested to eliminate any bias and is powered by proprietary indicators that have been shown to drive stock prices. Trained exclusively on public, compliant data, the model transforms complex company disclosures and market cues into validated, institutional-grade predictions with high accuracy and reliability. And all the while avoiding hallucination, overfitting, hindsight bias, and cherry-picking, all of which commonly plague traditional backtesting and other approaches.

“We are at an inflection point in fintech where predictive AI will become fundamental to investment strategies,” said Sid Ghatak, Founder and CEO of Increase Alpha. “With years of academic research and real-world trials, Increase Alpha now delivers proven predictive capabilities that institutional investors can trust. Our goal isn’t to just create another model, but redefine how AI technology is applied in finance.”

“After seeing how Increase Alpha merged AI, data and hedge funds I decided to invest,” said Bartt Kellermann, CEO of Battle of the Quants. “This combination is so completely unique and effective that they have the potential to reimagine the entire hedge fund space.”

Increase Alpha began as a long-term research project at Villanova University, where Ghatak served as a professor. The original hypothesis was that when the correct public data is paired with the right prediction engine, it could consistently forecast stock market movements. This methodology is validated through eight years of academic research and four years of real-time trials. Today, the predictive engine is being piloted by several of the world’s largest hedge funds, with licensing discussions underway.

Ghatak brings deep experience from AI governance and fintech. He currently serves as the Chief Technical Advisor at the National Artificial Intelligence Association and collaborates with The White House and Congress on AI legislation. Formerly, he served as a Director of the Data & Analytics Center of Excellence at the U.S. General Services Administration, co-authoring the federal AI Maturity Model to enable the adoption of AI within the public sector.

Following its seed round, Increase Alpha is focused on its go-to-market execution—working with hedge fund managers, Chief Investment Officers, and data buyers as they explore the product for technical validation and business understanding. Even in its nascent form, Increase Alpha has already rolled out pilots and trials for several top tier funds and is in the process of onboarding many more.

About Increase Alpha

Increase Alpha, LLC, founded by Sid Ghatak is a Washington, DC–based fintech company building a proprietary equity predictive signal engine. Powered by proprietary deep learning models and validated through rigorous forward-testing, the engine is born from a long-term research project and is validated through third-party research.

To learn more about Increase Alpha, visit https://www.increasealpha.com/

For inquiries, please contact Emely Reyes ([email protected])

SOURCE Increase Alpha

NetSuite helps rapidly growing pet supplement brand scale to over $200 million in annual revenue, attract venture capital investment, and expand into new retail channels

LAS VEGAS, Oct. 7, 2025 — SuiteWorld — PetLab Co., the pet wellness brand, is using Oracle NetSuite to support its mission to deliver breakthrough pet health with supplements crafted from premium, science-backed ingredients. With NetSuite, PetLab Co. has been able to scale to over $200 million in annual revenue by taking advantage of an integrated business system to automate financial processes, optimise inventory, and make data-led decisions.

Founded in London in 2018, PetLab Co. was inspired by co-founder and co-CEO Chris Masanto’s experience treating his pet dog for arthritis and has rapidly established itself as a leading direct-to-consumer pet supplement brand across the US, Canada, and the UK. As it expanded, PetLab co. quickly outgrew its accounting system, which struggled to cope with its multi-country operations and limited visibility into its business performance. To address these challenges and establish a scalable foundation to support its future growth, PetLab Co. implemented NetSuite’s enterprise resource planning (ERP) system in 2021 to consolidate its financial processes, manage its inventory, and enable its teams to make data-led decisions. Supported by the robust financial management capabilities in NetSuite, PetLab Co. attracted significant investment in 2025 to support further research and development and expand into bricks-and-mortar stores.

“PetLab Co. is committed to developing the best products to address the systemic issues impacting our pets, and to do that, we need the best systems,” said Tony Morreale, chief financial officer, PetLab Co. “NetSuite gives us a single source of truth for our finances, tight spend controls, and a solid foundation that has helped attract investment. It’s more than just software; it’s a strategic partner that has helped us scale efficiently and is powering the next phase of our growth.”

With NetSuite, PetLab Co. has benefitted from a scalable financial system to consolidate and automate its global financial operations. NetSuite has helped PetLab Co.’s finance team to finalise month-end processes 80 percent faster, better manage its cash flow, and accurately track the value of its assets over time. PetLab Co. also uses NetSuite as its command centre to process online sales, automate bank reconciliations, and connect to third-party logistics providers to fulfil orders and accurately track and manage its inventory. PetLab Co. partnered with NetSuite Solution Provider NoBlue2 on its implementation and to enhance its use of the suite.

“The pet care segment is growing rapidly, and PetLab Co. has attracted a loyal customer base thanks to its science-backed products and digital-first approach,” said Nicky Tozer, senior vice president, Europe, Middle East and Africa (EMEA), Oracle NetSuite. “With NetSuite, PetLab Co. has a partner that shares its data-led philosophy and will help support it across new geographies and sales channels.”

About Oracle NetSuite
For more than 25 years, Oracle NetSuite has helped organizations of all sizes reach their goals faster and more efficiently. NetSuite provides an integrated business system with embedded AI that delivers powerful financial management, supply chain, customer experience, and HR capabilities. Relied on by more than 43,000 customers in 220 countries and dependent territories, NetSuite is the #1 AI cloud enterprise resource planning (ERP) solution.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

About PetLab Co.
PetLab Co. is on a mission to deliver breakthrough pet health. Every day, we are realizing our vision to be the world’s most trusted pet health partner by providing innovative and clinically-tested health solutions, educating and engaging pet parents, and making ourselves available to the pet community. Together, with our team of industry veterans, PhD Nutritionists, Product Experts, Clinical Scientists, and Specialized Veterinarians, we employ an inquisitive and ambitious approach to R&D in the nutraceutical space that is grounded in (1) scientific evidence and testing and (2) creating new-to-science, proprietary active-ingredient blends that directly address the root causes of specific pet health issues. A recent powerful example of PetLab Co.’s commitment to groundbreaking R&D is ProBright® Advanced—a powder supplement that represents significant innovation in canine dental care.

SOURCE Oracle NetSuite

Investment structured through new investment vehicle, Clearlake Icon Partners VI, providing access to long-term committed capital to support both growth initiatives and acquisitions

WALTHAM, Mass., Oct. 7, 2025 — Constant Contact (the “Company”), a leading provider of digital marketing software for small businesses and nonprofits, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”), announced today that it has raised new capital via a Clearlake-managed dedicated fund, Icon Partners VI (“Icon VI”).

The transaction broadens Constant Contact’s investor base, while providing new and follow-on capital at a larger scale to support the Company’s accelerated growth trajectory and pursue acquisitions. Terms of the transaction were not disclosed.

As the largest independent player in the marketing automation space having pioneered the industry over three decades ago, Constant Contact helps its customer base of nearly half a million small businesses and non-profit organizations with their daily marketing needs across email, SMS, and social media, while providing a suite of analytics and AI-driven software products that enhance deliverability and audience engagement.

Clearlake re-established Constant Contact as a standalone company following the acquisition of Endurance International Group in 2021. Since partnering with Clearlake, the Company has experienced organic growth, increased profitability, and integrated four acquisitions that expanded its product suite and geographic reach. Additionally, investments into AI are expected to position Constant Contact at the forefront of AI adoption, enabling the Company to deliver enhanced customer experiences while simultaneously creating a more agile and scalable business model.  As a result, Constant Contact has more than tripled topline growth from ~2% at the time of the carve-out to ~7% today.

Icon VI, a dedicated Clearlake-managed single asset vehicle, was established with funding from institutional investors, led by Lexington Partners, as well as existing investors who have re-committed to the Company for the long-term. Clearlake will maintain its position as Constant Contact’s lead investor and the transaction will result in no change in governance to Constant Contact or to its executive leadership team, led by CEO Frank Vella.

“With this new equity capital, Constant Contact is poised to expand its market leadership and sharpen its competitive edge in marketing automation software,” said Behdad Eghbali, Co-Founder and Managing Partner, and James Pade, Partner and Managing Director, at Clearlake. “Over the past four years, Constant Contact has invested significantly in its product suite, enhancing its capabilities and implementing AI-driven solutions that aim to address the growing marketing needs of the small business owner of today. Through the continued efforts of Constant Contact’s management team and Clearlake’s support and implementation of its O.P.S.® framework, the Company has reached an exciting inflection point that lays the foundation for the next leg of growth acceleration at Constant Contact.”

“With Clearlake’s support over the last four years, we’ve assembled an experienced leadership team, redefined our product strategy, streamlined operations, and harnessed AI to elevate the customer experience,” said Frank Vella, CEO of Constant Contact.  “We are eager to build on this momentum in our next chapter of development and are excited to help small businesses leverage the power of software to make marketing less overwhelming. We handle the complexities so our customers can get back to running their business—not their marketing campaigns.”

Evercore acted as financial advisor and Paul Weiss, Sidley Austin, and Proskauer Rose provided legal counsel to Clearlake and Lexington Partners as part of the transaction.

About Constant Contact
Constant Contact makes digital marketing easy and effective for small businesses and nonprofits across the globe. Whether just starting or managing complex multi-channel campaigns, SMBs benefit from our powerful SaaS platform that delivers a simplified marketing experience in less time and with better results. With cutting-edge technology, best-in-class deliverability, and award-winning customer support, we help the small stand tall. Learn more at constantcontact.com.

About Clearlake
Clearlake Capital Group is a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies.  Founded in 2006, the firm has more than $90 billion of assets under management and has led or co-led over 400 investments globally.  With deep knowledge and operational expertise across the technology, industrials, and consumer sectors, Clearlake seeks to partner with experienced management teams, providing patient, long-term capital and aiming to drive value through its active hands-on operating approach, O.P.S.® (Operations, People, Strategy). Headquartered in Santa Monica, Clearlake maintains a global footprint with offices in Dallas, New York, London, Dublin, Luxembourg, Abu Dhabi, and Singapore.  For more information, please visit clearlake.com or follow us on LinkedIn.

SOURCE Constant Contact, Inc.